biotech · Chronic Inducible Urticaria · Chronic Spontaneous Urticaria · JSPR
Jasper Therapeutics
Jasper Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Redwood City, CA, US
- Employees
- 44
- Programs
- 13
- Drugs
- 13
- Patents
- 1
Jasper Therapeutics projects
7 ClinicalTrials.gov programs sponsored by Jasper Therapeutics.
Jasper Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Briquilimab
Jasper Therapeutics
Chronic Urticaria
1 trial -
Briquilimab
Jasper Therapeutics
Chronic Spontaneous Urticaria
1 trial -
Briquilimab
Jasper Therapeutics
Urticaria Chronic
1 trial -
Briquilimab
Jasper Therapeutics
Chronic Inducible Urticaria
1 trial -
EPINEPHRINE , Briquilimab
Jasper Therapeutics
Chronic Inducible Urticaria
1 trial -
Humanized anti-CD117 Monoclonal Antibody (JSP191)
Jasper Therapeutics
SCID
1 trial -
JSP-CP-011
Jasper Therapeutics
Chronic Spontaneous Urticaria
1 trial
Frequently asked questions
How many clinical projects does Jasper Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.